Drug and Health Product Submissions Under Review (SUR)

Overview of Submissions Under Review

The Submissions Under Review (SUR) lists help increase transparency around the regulatory review of drugs and health products in Canada by Health Canada. These lists include information about new drug submissions, supplemental submissions, and items that have been completed. ([canada.ca](https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/submissions-under-review.html))

What the SUR Lists Show

The SUR lists contain information on:

• New drug submissions currently under review (active substances, biosimilars, etc.);
• Supplemental submissions under review for new uses or indications;
• New drug submissions that have been completed;
• Supplemental submissions that have been completed.

Completed submissions are moved off the “under review” lists once a final regulatory decision is made or the submission is cancelled. Final decisions may include issuance of a Notice of Compliance (NOC) or cancellation by the sponsor.

Accessing the Lists

Each SUR list — including new drug submissions and supplemental submissions — can be downloaded and viewed. †The lists are regularly updated (e.g., monthly).

The information typically includes:

• Medicinal ingredient or health product name;
• Therapeutic area classification;
• Year and month the submission was accepted into review;
• Company (sponsor) name and classification details for newer entries.

COVID‑19 and Special Review Cases

The SUR page also highlights submissions made under specific provisions for use in relation to COVID‑19 (e.g., Interim Order filings). These can be found by filtering for “COVID” on the lists. Products submitted during the transition from interim orders to standard regulatory review may appear in both sections.

For information on authorized COVID‑19 treatments and vaccines, Health Canada maintains a dedicated portal.

Regulatory Decisions and Outcomes

Once a submission completes review and receives a decision — either approval (Notice of Compliance) or cancellation — it is moved to the “completed” lists. Detailed regulatory decision summaries and rationale can be found through the Health Canada drug and health product portal and the Notice of Compliance Database.